HealthyDirect · GrowthFit for a long SIP
ITI Mid Cap Fund
ITI Mutual FundEquity Scheme - Mid Cap Fund5.6 years
The scheme seeks to seek to generate long term capital appreciation by predominantly investing in equity and equity related securities of mid cap stocks.
- NAV
- 23.543
- 30 Oct 2026
- 1Y
- -1.3%
- Trailing CAGR
- Upside capture
- +94%
- Vs NIFTY MIDCAP 150 TRI
- Downside capture
- +91%
- Lower is better
Buying brief
Should you add this fund?
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
In three lines
Fits if · The fund beat the category median in 100% of rolling 3-year windows.
Fits if · Three-year return is above the category median.
Buy checklist
History depth
Pass
5.6 years of path to read.
Engine status
Pass
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Expense ratio
Pass
0.91% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -22.7%. Ask whether you can hold through a similar fall.
Vs category
Pass
100% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Watch
Alok Ranjan · 0.5 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 18.6% of the portfolio.
Evidence supports a shortlist - confirm with peers before you buy elsewhere.
Before you buy or SIP
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 23%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
If you start a SIP here, diary a 90-day check and an annual review - don’t react to every NAV print.
NAV
Path not in current snapshots
n/a
Returns
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
- 1Y-1.3%
- 3Y+17.7%
- 5Y+14.0%
- 10Yn/a
- SI+16.4%
SIP XIRR
Equal monthly instalments to latest NAV
- 1Y-5.2%
- 3Y+5.0%
- 5Y+14.7%
- 10Yn/a
- Since inception
- +16.4%
- Calendar-day CAGR
- Excess 1Y
- +1.4%
- Category median, same plan and option
- 3Y win rate
- +100%
- Windows beating the median
- 3Y percentile
- 94
- Vs comparable share classes
- SIP 3Y XIRR
- +5.0%
- Simulated monthly SIP
- Worst rolling 3Y
- +16.5%
- 651 daily-ending windows
- Median rolling 3Y
- +25.1%
- Calendar-day CAGR
- Positive rolling 5Y
- +100%
- 160 daily-ending windows
Official benchmark
Date-aligned against NIFTY MIDCAP 150 TRI. Capture ratios use common month-end observations through 30 Oct 2026.
- 1Y excess
- +3.1%
- Fund minus TRI
- 3Y excess
- +3.9%
- Fund minus TRI
- Upside capture
- +94%
- Benchmark-up months
- Downside capture
- +91%
- Lower is better
Drawdown
Peak to trough from a running NAV high, with the path and recovery episodes.
- Max drawdown
- -22.7%
- Worst peak-to-trough
- Current
- -11.2%
- Below last peak
- Current spell
- 60 days
- Days below latest peak
- Time below peak
- +86%
- NAV observations
Drawdown
Path not in current snapshots
n/a
- Average recovery
- 14 days
- 75 recovered episodes
- Longest recovery
- 351 days
- Trough to prior peak
9 Nov 2021 – 6 Jun 2023
Trough 20 Jun 2022 · recovered in 351 days
-22.7%
27 Sept 2024 – 2 Jan 2026
Trough 28 Feb 2025 · recovered in 308 days
-22.3%
2 Jan 2026 – 7 May 2026
Trough 31 Mar 2026 · recovered in 37 days
-14.2%
31 Aug 2026 – open
Trough 23 Oct 2026 · not recovered
-13.8%
Dimensions
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
94
Vs category
59
Consistency
83
Risk-adjusted
59
Drawdown
43
Mean
68
Decision
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Healthy
Buying stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Why this status
- No material deterioration, cost shock, or persistent category underperformance in the current evidence set.
Supporting reads
- The fund beat the category median in 100% of rolling 3-year windows.
- Three-year return is above the category median.
- Risk-adjusted return sits above the documented risk-free proxy.
Portfolio
30 Sept 2026 · 96 holdings · top 10 are 18.6%.
- Top 5
- 10.4%
- Top 10
- 18.6%
- Largest holding
- 2.9%
- Effective holdings
- 81.5
The Federal Bank Ltd
Financial
2.9%
Fortis Healthcare Ltd
Healthcare
2.0%
One 97 Communications Ltd
Industrials
1.9%
Radico Khaitan Ltd
Consumer Staples
1.8%
IDFC First Bank Ltd
Financial
1.8%
Worth investigating
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
Baroda BNP Paribas Mid Cap Fund
Baroda BNP Paribas Mutual Fund
- 1Y
- +0.8%
- 3Y
- +15.3%
- Vol
- 14.5%
- Max DD
- -18.6%
- Sharpe
- 0.70
- 3Y win
- +97%
- Lower volatility
- Shallower drawdown
- Lower TER
Caveat: Lower trailing returns
Union Midcap Fund
Union Mutual Fund
- 1Y
- +0.7%
- 3Y
- +15.6%
- Vol
- 16.2%
- Max DD
- -21.3%
- Sharpe
- 1.28
- 3Y win
- +76%
- Lower volatility
- Shallower drawdown
Caveat: Higher TER · Lower trailing returns
Axis Midcap Fund
Axis Mutual Fund
- 1Y
- +1.3%
- 3Y
- +16.1%
- Vol
- 14.9%
- Max DD
- -29.4%
- Sharpe
- 0.82
- 3Y win
- +41%
- Lower volatility
- Lower TER
Caveat: Deeper drawdown · Lower trailing returns
DSP Midcap Fund
DSP Mutual Fund
- 1Y
- -4.4%
- 3Y
- +12.6%
- Vol
- 16.2%
- Max DD
- -32.7%
- Sharpe
- 0.66
- 3Y win
- +49%
- Lower volatility
- Lower TER
Caveat: Deeper drawdown · Lower trailing returns
Edelweiss Mid Cap Fund
Edelweiss Mutual Fund
- 1Y
- -2.0%
- 3Y
- +19.0%
- Vol
- 17.1%
- Max DD
- -39.2%
- Sharpe
- 0.78
- 3Y win
- +100%
- Lower TER
- Higher trailing returns
Caveat: Higher volatility · Deeper drawdown